Navigation Links
Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium

Tampa, FL (PRWEB) July 26, 2013

Delegates will gain from the vast knowledge of Nobel Laureate, Dr. Oliver Smithies, during his plenary session “Where Do Ideas Come From” at ISPE’s Biotechnology, a two-day Symposium August 27-28, 2013 in Durham, NC.

Smithies is the Weatherspoon Eminent Distinguished Professor of Pathology and Laboratory Medicine at University of North Carolina. In the 1950s, he described the first high resolution electrophoresis system (starch gel), and discovered that normal humans have unsuspected inherited differences in their proteins. His technique of starch-gel electrophoresis opened vast areas of new study. With this technique, Smithies uncovered protein polymorphisms in normal persons and worked on the heredity of several blood proteins.

In 1985, Smithies described his second ground-breaking technique – the use of homologous recombination to alter a human gene in a living cell. With this technique, he has determined how genes affect blood pressure in healthy persons, and how the same genes influence the kidney problems that affect some people with diabetes.

In addition to Smithies’ presentation, Dr. James Talton, CEO Nanotherapeutics and David Doleski, Director, Division of Good Manufacturing Practice Assessment, CDER, FDA, will present. Talton is a co-inventor of Nanotherapeutics' technologies and has several authored peer-reviewed publications and book chapters involved in drug delivery systems with a primary focus in drug analysis and controlled release formulations, pharmacokinetics, and pulmonary drug delivery.

“These expert speakers will serve as outstanding leads into this new conference that explores advances in biopharmaceutical manufacturing, facility design and integration to help companies develop and validate future projects and next-generation manufacturing systems,” said Nancy Berg, President/CEO of ISPE.

Attendee registration is open. Those interested can learn more at

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the world’s largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA and offices in Brussels, Belgium, Singapore and Shanghai, China. Visit for more information.


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
2. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
3. Une plainte contre une organisation du Prix Nobel pour diffamation et concurrence deloyale est déposée pour la première fois
4. Erste Klage gegen Nobelpreis-Organisation wegen Verleumdung und unlauterem Wettbewerb eingereicht
5. First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
6. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
7. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
8. Syngentas Mary-Dell Chilton named 2013 World Food Prize laureate
9. The Energy Scientific World Acclaims the Global Energy Prize 2012 Laureates
10. Laureate Biopharma Names James D. Utterback to Board of Directors
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):